HALO Share Price

Open 11.81 Change Price %
High 12.11 1 Day 0.00 0.00
Low 11.28 1 Week -1.50 -11.64
Close 11.39 1 Month -0.27 -2.32
Volume 2193344 1 Year 1.29 12.77
52 Week High 14.38
52 Week Low 6.96
HALO Important Levels
Resistance 2 12.16
Resistance 1 11.84
Pivot 11.59
Support 1 10.94
Support 2 10.62
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
DRYS 1.87 0.00%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
LINE 0.18 12.50%
ATEA 1.90 11.76%
ATEA 1.90 11.76%
KITD 0.30 11.11%
SGYPU 10.75 10.26%
LPHI 0.24 9.09%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
THTI 0.15 -40.00%
More..

Halozyme Therapeutics, Inc. (NASDAQ: HALO)

HALO Technical Analysis 3
As on 13th Jan 2017 HALO Share Price closed @ 11.39 and we RECOMMEND Buy for LONG-TERM with Stoploss of 10.16 & Buy for SHORT-TERM with Stoploss of 11.22 we also expect STOCK to react on Following IMPORTANT LEVELS.
HALO Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
HALO Other Details
Segment EQ
Market Capital 613046848.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.halozyme.com
HALO Address
HALO
11388 Sorrento Valley Road
San Diego, CA 92121
United States
Phone: 858-794-8889
Fax: 858-704-8311
HALO Latest News
Interactive Technical Analysis Chart Halozyme Therapeutics, Inc. ( HALO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Halozyme Therapeutics, Inc.
HALO Business Profile
Halozyme Therapeutics, Inc. is a biopharmaceutical company. The Company�s research focuses primarily on human enzymes that alter the extracellular matrix. The Company�s pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. The product candidates in its pipeline are based on rHuPH20, a patented human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA), a naturally occurring substance that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Pfizer Inc. (Pfizer), Baxter Healthcare Corporation (Baxter), ViroPharma Incorporated (ViroPharma) and Intrexon Corporation (Intrexon), with three product candidates.